title: Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
abstract: Serum concentrations of luteinizing hormone (LH), testosterone, prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) were measured in 16 patients with advanced prostatic cancer before and after treatment with luteinizing hormone-releasing hormone (LHRH) analogue. An initial rise of serum LH and testosterone levels was observed on day 2 of the treatment. Subsequently, serum concentrations of PAP and PSA showed a transient increase on day 5 of the treatment. This indicates that LHRH analogues had better be given in combination with antiandrogens in patients with metastatic carcinoma of the prostate.
authors: Department of Urology, Yamagata University, School of Medicine, Japan.
authors: I
authors: I
authors: Sasagawa
authors: Y
authors: Y
authors: Kubota
authors: T
authors: T
authors: Nakada
authors: H
authors: H
authors: Suzuki
authors: J
authors: J
authors: Hirano
authors: O
authors: O
authors: Sugano
authors: H
authors: H
authors: Kato
authors: A
authors: A
authors: Imamura
authors: K
authors: K
authors: Mastushita
authors: Y
authors: Y
authors: Onmura
authors: M
authors: M
authors: Saito
authors: M
authors: M
authors: Adachi
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D002277:Carcinoma / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007279:Injections, Subcutaneous; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D011863:Radioimmunoassay; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D013739:Testosterone; D007986:Luteinizing Hormone; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D016729:Leuprolide